Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

60.89
-0.0400-0.07%
Post-market: 60.890.00000.00%19:30 EDT
Volume:352.29K
Turnover:21.32M
Market Cap:2.93B
PE:-25.32
High:62.45
Open:61.40
Low:58.80
Close:60.93
52wk High:72.64
52wk Low:9.63
Shares:48.16M
Float Shares:27.63M
Volume Ratio:1.02
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4052
EPS(LYR):-2.3824
ROE:-33.17%
ROA:-22.08%
PB:7.16
PE(LYR):-25.56

Loading ...

MBX Biosciences Begins Pivotal Phase 3 Canvuparatide Trial

TIPRANKS
·
Aug 27

MBX Biosciences Doses First Patient in Phase 3 oPTimize Trial of Once-Weekly Canvuparatide for Hypoparathyroidism

Reuters
·
Aug 27

Mbx Biosciences, - Phase 3 Optimize Trial to Enroll About 160 Adults with Hypoparathyroidism

THOMSON REUTERS
·
Aug 27

MBX Biosciences Price Target Announced at $88.00/Share by JP Morgan

Dow Jones
·
Aug 22

U.S. Research Roundup-Health Catalyst, Nektar Therapeutics, TIC Solutions

Reuters
·
Aug 21

13D Filings

Dow Jones
·
Aug 15

Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating

MT Newswires Live
·
Aug 10

MBX Biosciences, Inc. (MBX) Gets a Buy from Mizuho Securities

TIPRANKS
·
Aug 08

MBX Biosciences price target raised to $88 from $70 at Barclays

TIPRANKS
·
Aug 07

Analysts Offer Insights on NA Companies: BillionToOne, Inc. Class A (BLLN) and MBX Biosciences, Inc. (MBX)

TIPRANKS
·
Aug 07

MBX Biosciences Shares Lower After Q2 Loss Widens

MT Newswires Live
·
Aug 06

MBX Biosciences, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

MBX Biosciences Advances Canvuparatide and Obesity Pipeline

TIPRANKS
·
Aug 06

Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, vs. FactSet Est of $0.63 Loss

MT Newswires Live
·
Aug 06

MBX Biosciences Posts Corporate Presentation on Precision Peptide Programs for Endocrine, Metabolic Diseases

Reuters
·
Aug 06

MBX Biosciences Q2 FY26 Net Loss Widens to $37.1 Million; R&D Expenses Rise to $31 Million

Reuters
·
Aug 06

MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) Estimate

Benzinga Earnings
·
Aug 06

Press Release: MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights

Dow Jones
·
Aug 06

Mizuho Securities Sticks to Its Buy Rating for MBX Biosciences, Inc. (MBX)

TIPRANKS
·
Jul 29

MBX Biosciences price target raised to $90 from $60 at UBS

TIPRANKS
·
Jul 23